• ID: 2485033
  • Book
  • 510 Pages
  • Elsevier Science and Technology
1 of 4
Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunity within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference.

- Multi-contributed book and chapters are written by contributors who are experts in their field- Provides perspectives from those involved in all aspects of pharmacogenomics-including academic, regulatory, economic, industry and medical-to illustrate how all of the pieces fit together and where the challenges may be- Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications- Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Note: Product cover images may vary from those shown
2 of 4


1 Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications 2 Translating Pharmacogenomic Research to Therapeutic Potentials 3 Governmental and Academic Efforts to Advance the Field of Pharmacogenomics (PGRN CPIC, PharmGKB)

Section 2

4a Pharmacogenomics in Cancer Therapeutics 4b A Look to the Future:  Cancer epigenetics 5a Pharmacogenomics in Cardiovascular Diseases 5b A Look to the Future: Cardiovascular Pharmaco-epigenetics 6a Pharmacogenomics in Psychiatry Disorders 6b A Look to the Future: Epigenetics in psychiatric disorders and treatment 7 Role of Pharmacogenomics in Diabetes and Other Therapeutic Areas 


8a Molecular Approaches, Models, and Techniques in Pharmacogenomic Research and Development 8b Molecular Approaches, Models, and Techniques in Pharmacogenomic Research and Development 9a Incorporating Pharmacogenomics in Drug Development Part 1:  Rational  study designs for pharmacogenetic research and therapy
A perspective  from academia 9b Incorporating Pharmacogenomics in Drug Development Part 2:  A perspective from industry 10 Ethnobridging and Pharmacogenomics


11 Beyond ELSIs
Where to from here? From 'Regulator' to Anticipating and Shaping the Innovation Trajectory in Personalized Medicine 12 The Economics of Pharmacogenomics


13 Integrating Genomics into Pharmacy Education and Practice: Pharmacogenomics is not enough

Note: Product cover images may vary from those shown
3 of 4


4 of 4
Lam, Yui-Wing Francis
Dr. Lam is Professor of Pharmacology at the University of Texas Health Science Center San Antonio (UTHSCSA). His editing experience included the first edition of Pharmacogenomics as well as being the lead editor of another published book entitled "Herbal Supplements - Drug Interactions. Scientific and Regulatory Perspectives”. He is also a co-author for a book chapter on pharmacogenetics in six consecutive editions of the textbook "Pharmacotherapy: A Pathophysiologic Approach”. Dr. Lam designed and continues to direct a graduate course "Molecular and Pharmacological Basis of Therapeutics” since 2002 for the UTHSCSA and the College of Pharmacy at the University of Texas at Austin. He has organized and participated in international and national symposia on topics related to personalized and molecular medicine, and is a scientific councilor for the Pacific Rim Association for Clinical Pharmacogenetics.
Cavallari, Larisa H.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown